Relay Therapeutics director granted 32,947 stock options

Relay Therapeutics director Douglas S. Ingram received a grant of stock options covering 32,947 shares of common stock.

Rhea-AI Filing Summary

Relay Therapeutics director Douglas S. Ingram received a grant of stock options covering 32,947 shares of common stock. The options carry an exercise price of $14.09 per share and were granted as a compensation-related award, not an open-market purchase or sale.

According to the terms, the award vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders following that grant date. After this grant, Ingram holds options for 32,947 underlying shares.

Insider Trade Summary

Grant/Award: 32,947 shares

Grant/Award 1 txn

Insider INGRAM DOUGLAS S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,947	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 32,947 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Key Figures

Option grant size: 32,947 shares Exercise price: $14.09 per share Post-transaction options: 32,947 shares +2 more

5 metrics

Option grant size 32,947 shares Stock options granted June 9, 2026

Exercise price $14.09 per share Stock option strike price

Post-transaction options 32,947 shares Total underlying shares following grant

Expiration date June 8, 2036 Option expiration

Vesting condition Earlier of 1 year or next annual meeting Vesting schedule from June 9, 2026 grant

Key Terms

Stock Option (Right to Buy), grant/award acquisition, Common Stock, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders financial

"vests in full on the earlier to occur of ... the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Relay Therapeutics (RLAY) director Douglas S. Ingram report on this Form 4?

Douglas S. Ingram reported receiving a grant of stock options for 32,947 shares of Relay Therapeutics common stock. The options are a compensation-related award, not an open-market trade, and increase his derivative holdings tied to the company’s equity.

What are the key terms of the Relay Therapeutics (RLAY) stock options granted to Douglas S. Ingram?

The grant covers 32,947 shares of common stock with an exercise price of $14.09 per share. The options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders.

Is Douglas S. Ingram buying or selling Relay Therapeutics (RLAY) stock in this Form 4?

This Form 4 shows an acquisition of stock options as a grant, not a market purchase or sale of Relay Therapeutics shares. The transaction code is A, indicating a grant or award acquisition of derivative securities tied to common stock.

How many Relay Therapeutics (RLAY) options does Douglas S. Ingram hold after this transaction?

Following this grant, Douglas S. Ingram holds stock options covering 32,947 underlying shares of Relay Therapeutics common stock. This filing does not show additional derivative positions, so the reported post-transaction total equals the size of the new grant.

When do Douglas S. Ingram’s Relay Therapeutics (RLAY) options expire and vest?

The options were granted on June 9, 2026 and vest in full on the earlier of the first anniversary of that date or the next annual stockholders’ meeting. They carry an expiration date of June 8, 2036, giving a long exercise window.

What does the transaction code A mean in the Relay Therapeutics (RLAY) Form 4 for Douglas S. Ingram?

Transaction code A signifies a grant, award, or other acquisition of derivative securities. Here, it reflects a stock option grant to Douglas S. Ingram, rather than an open-market buy or sell of Relay Therapeutics common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

INGRAM DOUGLAS S

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.09	06/09/2026		A		32,947		(1)	06/08/2036	Common Stock	32,947	$0	32,947	D

Explanation of Responses:

1. This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)